|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Quidel Corporation
| | | Phone: | (858) 552-1100 | Year Established: | 1979 | Ticker: | QDEL | Exchange: | NASDAQ | Main Contact: | John D. Tamerius, Ph.D., Senior VP, Strategic & External Affairs | | Other Contacts: | Edward K. Russell, Senior VP, Global Commercial Operations Werner Kroll, Senior VP, R&D Robert J. Bujarski, Senior VP, General Counsel and Corporate Secretary Michael D. Abney, Jr., Senior VP, Distribution Randall J. Steward, CFO Douglas C. Bryant, President & CEO
| | Company Description | Quidel is a California-based leading manufacturer of diagnostic healthcare solutions serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.
Quidel commenced operations in 1979 and launched its first products in 1984. Since that time, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions. Our core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. Their current products fall into these categories: (1) lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. Additional molecular and Sofia tests are currently in development or in clinical trials as part of a robust product pipeline. | |
|
|
|
|
|